CMS Moves to Tighten Medicare Advantage Directory Oversight
The Centers for Medicare and Medicaid Services is proposing a rule that would force Medicare Advantage plans to verify their provider directories every 90 days beginning in 2028, a direct response to one of the most persistent friction points in managed care: inaccurate network listings that leave beneficiaries stranded between coverage rules and real-world access to care.
If a plan incorrectly lists an out-of-network clinician as in-network, members who seek care from that provider would be protected from paying more than the in-network cost-sharing rate. In practical terms, the rule would shift the financial burden of directory errors away from patients and back toward insurers, where the responsibility for maintaining accurate networks belongs.
A directory mismatch is not an administrative nuisance. It can delay specialty care, produce surprise bills, and force older adults to cancel or postpone visits after a long search for an in-network clinician who turns out not to be one. For people living with complex chronic illness, even a single bad network listing can disrupt treatment continuity, especially when the next available specialist may be hours away or booked for months.
The proposal also reaches beyond insurer directories and into the pharmacy supply chain. CMS wants new transparency requirements for pharmacy benefit managers, the intermediaries that influence drug pricing, formulary placement, and patient cost sharing. Those changes are part of a broader federal push to make the mechanics of managed care less opaque and more accountable to enrollees.
Why Directory Accuracy Has Clinical Consequences
Network accuracy sounds bureaucratic, but the downstream effects are clinical. A patient with diabetes who cannot confirm an endocrinology appointment, a heart failure patient who is forced to switch cardiology practices, or an oncology patient who loses access to a preferred infusion center can all experience treatment delays that reverberate far beyond a billing dispute.
The problem is especially corrosive in Medicare Advantage because beneficiaries often rely on plan directories as the primary map for care. When that map is wrong, patients can end up making decisions based on false assurances. The result can be abandoned appointments, repeated phone calls, and last-minute substitutions that fracture continuity of care. Older adults, people with limited mobility, and those who do not navigate health systems comfortably are hit hardest.
CMS’s proposal recognizes that accuracy cannot be treated as a once-a-year housekeeping task. A 90-day verification cycle would push plans to update directories more often and should, at least in theory, reduce the lag between provider changes and beneficiary-facing information. In a market where physicians join and leave networks, hospitals merge, and practice locations shift, stale data quickly becomes a patient safety issue.
Cost Sharing Protections Could Cushion the Harm of Bad Data
The plan to cap cost sharing at the in-network level when a member relies on an inaccurate directory listing is the most immediate consumer protection in the rule. It would prevent patients from absorbing the consequences of insurer errors when they act in good faith on information the plan itself posted.
That policy has a clear bedside logic. Patients should not be penalized because a directory promised access that did not exist. The financial shock from an out-of-network claim can be severe enough to alter future care-seeking behavior, particularly among older adults on fixed incomes. Even when the amount is not catastrophic, the uncertainty alone can make people avoid seeking care until symptoms worsen.
The proposal may also reduce a subtle but important deterrent effect. When beneficiaries fear they will be hit with higher charges, they often delay care or overinvest time and energy in verifying coverage before each appointment. By aligning cost exposure with the plan’s published information, CMS is trying to restore a more trustworthy relationship between the insurer and the enrollee.
PBM Transparency Moves Into the Same Regulatory Package
The rule extends into pharmacy benefit manager oversight as well, reflecting growing federal concern about how PBMs shape access to medications and the prices patients ultimately face at the counter. While the details of the transparency provisions matter, the policy direction is clear: the agency wants more visibility into the intermediaries that sit between insurers, pharmacies, drug manufacturers, and beneficiaries.
That matters because drug coverage is one of the most common places where paperwork and price architecture become a clinical obstacle. A beneficiary may discover at the pharmacy that a medication is excluded, placed on a high-cost tier, or subject to prior authorization, even after believing the plan offered broad coverage. For patients managing multiple prescriptions, those surprises can interrupt adherence and trigger substitution with less effective or less tolerated alternatives.
Pharmacy cost-sharing confusion often functions like a hidden form of nonadherence. A prescription that is technically covered but unaffordable is, from the patient’s perspective, effectively inaccessible. Transparency rules aimed at PBMs will not solve every pricing problem, but they could make the flow of information less distorted and help regulators identify where costs are being marked up or obscured.
A Measured Federal Response to a Systemic Access Problem
CMS is not trying to redesign Medicare Advantage from scratch. The proposal targets two recurring failure points: inaccurate directories and hidden medication-related decision-making. Both sit at the intersection of coverage and care delivery, where small administrative defects can translate into real medical harm.
The timing is notable because Medicare Advantage enrollment continues to place more beneficiaries inside a managed-care structure that depends heavily on digital directories and negotiated networks. As enrollment grows, so does the scale of the problem when those systems fail. A misleading provider list in a small plan affects fewer people than the same error in a national plan with millions of members.
The next step will be the rulemaking process itself, where insurers, pharmacy middlemen, patient advocates, and other stakeholders will press on the costs and feasibility of the new requirements. Even so, the regulatory signal is unambiguous: CMS is treating inaccurate directories and opaque drug middleman practices as patient access problems, not mere compliance issues.
What the final rule can and cannot do will depend on enforcement. Without meaningful auditing, penalties, and rapid correction mechanisms, directory accuracy can degrade again as soon as the pressure lifts.